Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Acute Renal Failure (ARF) Market Growth in 2025?
The market for acute renal failure (ARF) has been expanding significantly in the last few years. It is projected to rise from a worth of $6.09 billion in 2024 to approximately $6.62 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 8.6%. Factors contributing to the surge during the historical period include the increasing elderly population, the growing prevalence of sepsis, advancements in diagnostic techniques, healthcare initiatives from the government, and escalating instances of nephrotoxic medication.
What Is the Forecast for the Acute Renal Failure (ARF) Market Size Through 2029?
The market for acute renal failure (ARF) is projected to experience significant expansion in the coming years. The market value is expected to reach $9.09 billion by 2029, growing at a compound annual growth rate (CAGR) of 8.3%. This anticipated market growth during the forecast period is primarily due to the proliferation of home-based dialysis solutions, emerging markets, the establishment of renal biomarkers, r&d for novel therapeutic drugs, and the growing demand for non-invasive diagnostics. Key trends expected during the forecast period include advancements in continuous renal replacement therapy (CRRT), 3D bioprinting of renal tissue, wearable biosensors, next-generation dialysis machines, and nanotechnology-inspired drug delivery systems.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21083&type=smp
What are the Key Market Players in Acute Renal Failure (ARF) Market and How They’re Evolving?
Major companies operating in the acute renal failure (ARF) market are Pfizer Inc., Novartis AG, LG Chem Ltd., Medtronic plc, Fresenius Medical Care AG & Co. KGaA, Asahi Kasei Corporation, Baxter International Inc., Astellas Pharma Inc., Syensqo, Dr. Reddy’s Laboratories Limited, Zydus Lifesciences Limited, NIKKISO Co., Ltd., Quark Pharmaceuticals Inc., NIPRO Corporation, Alloksys Life Sciences B.V., AM-Pharma B.V., Sentien Biotechnologies, MediBeacon LLC, Angion Biomedica Corp., Atox Bio Ltd.
What Are the Primary Growth Drivers in the Acute Renal Failure (ARF) Market?
The escalating occurrence of chronic kidney disorders is anticipated to stimulate the expansion of the acute renal failure (ARF) market in the future. Chronic kidney disease (CKD) denotes a prolonged condition where the functionality of the kidneys is compromised, impeding efficient blood filtration. The escalating occurrence of CKD is due to increasing cases of diabetes, hypertension, obesity, aging populations, and lifestyle-related factors globally. Acute renal failure, distinguished by an unexpected loss of kidney functionality, can serve as a major instigator or aggravating factor for CKD by inducing permanent damage to kidney tissues, disrupting filtration effectiveness, and heightening the likelihood of progressive, long-term kidney malfunctions if not controlled appropriately. For instance, in June 2023, as stated in a report by Kidney Research UK, a non-profit organization based in the UK, approximately 7.2 million people in the UK are presently coping with chronic kidney disease, accounting for over 10% of the populace. Of these, 3.25 million are dealing with the disease’s advanced stages, while an additional 3.9 million are at the early stages. By 2033, the population affected by chronic kidney disease is expected to increase to 7.61 million. Hence, the escalating occurrence of chronic kidney disorders is propelling growth in the acute renal failure (ARF) market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21083&type=smp
What Are the Leading Segments in the Global Acute Renal Failure (ARF) Industry?
The acute renal failure (ARF) market covered in this report is segmented –
1) By Disease Type: Prerenal Acute Renal Failure, Renal Acute Renal Failure, Postrenal Acute Renal Failure
2) By Drug Type: Diuretics, Vasopressors, Erythropoiesis-Stimulating Agents (ESAS), Phosphate Binders, Calcium and Vitamin D Supplements, Antibiotics, Others Drugs
3) By Route of Administration: Oral, Intravenous
4) By Diagnosis: Computed Tomography (CT) Scan, Kidney Biopsy, Ultrasound
5) By End-Users: Clinics, Hospitals, Home Healthcare, Others End-Users
Subsegments:
1) By Prerenal Acute Renal Failure: Hypovolemia, Decreased Cardiac Output, Renal Artery Stenosis
2) By Renal Acute Renal Failure: Acute Tubular Necrosis, Glomerulonephritis, Interstitial Nephritis
3) By Postrenal Acute Renal Failure: Obstructive Uropathy, Bladder Outlet Obstruction, Kidney Stones
What Are the Key Market Trends in the Acute Renal Failure (ARF) Industry?
Leading firms in the acute renal failure (ARF) market are prioritizing the acquisition of regulatory approvals for their drugs, in an effort to broaden their reach and bolster their standing in treating severe acute kidney injury (AKI). Gaining regulatory approval signifies obtaining official permission from government or regulatory agencies for the promotion and public usage of pharmaceuticals, medical devices or treatments. For example, in February 2024, CalciMedica., a clinical-stage biopharmaceutical company based in the U.S, secured FDA approval for an Investigational New Drug (IND) application for a Phase 2 trial of Auxora, a drug aimed at treating severe AKI associated with acute hypoxemic respiratory failure (AHRF), a syndrome known for high fatality rate. The KOURAGE trial, a randomized, double-blind, and placebo-controlled study, aims to register around 150 patients afflicted with Stage 2 and 3 AKI alongside acute hypoxemic respiratory failure (AHRF). This study aims to ascertain the effectiveness of Auxora through five daily doses by analyzing the quantity of days lived without the necessity of ventilators or dialysis subsequent to 30 days of the treatment.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/acute-renal-failure-arf-global-market-report
What Is the Regional Outlook for the Acute Renal Failure (ARF) Market?
North America was the largest region in the acute renal failure (ARF) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute renal failure (ARF) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21083
This Report Delivers Insight On:
1. How big is the acute renal failure (arf) market, and how is it changing globally?
2. Who are the major companies in the acute renal failure (arf) market, and how are they performing?
3. What are the key opportunities and risks in the acute renal failure (arf) market right now?
4. Which products or customer segments are growing the most in the acute renal failure (arf) market?
5. What factors are helping or slowing down the growth of the acute renal failure (arf) market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
